Plain-English translation of NCT06375733 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a combination of two drugs — and — in people with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer). Researchers want to see if this medication combination is safe and whether it can help shrink the cancer in people whose lymphoma has come back or stopped responding to earlier treatments. The trial is being conducted at multiple hospitals and will involve about 51 patients.
People with aggressive B-cell lymphoma that returns or doesn't respond to standard treatments have very few options left, and outcomes are often poor. This trial exists to see if this new treatment combination might offer hope to patients who have already tried multiple rounds of chemotherapy and other therapies.
You likely qualify if…
You likely don't qualify if…
You will receive the two medications together — this appears to be given at a clinic or hospital setting. The trial has two phases: Phase 1b focuses on finding the right dose and checking for side effects in a smaller group, and Phase 2 will test how well the treatment works in a larger group. You'll have regular visits for blood tests, scans to measure your tumors, and check-ins with your doctor to monitor your health and any side effects. The exact schedule of visits and duration of treatment will be explained to you once you enroll.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Genfleet Therapeutics (Shanghai) Inc.
Enrollment target
~51 participants
Started
March 2024
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yolanda Zeng
Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.